Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Maier, Julia ^a   Traenkle, Bjoern ^a   Rothbauer, Ulrich ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; NANOBODY; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; WITHAFERIN A; WITHANOLIDE;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; CELL SURVIVAL; CHEMISTRY; COMPUTER SYSTEM; DOG; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE; GENE SILENCING; HUMAN; MDCK CELL LINE; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SYSTEMS; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENCE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SINGLE-DOMAIN ANTIBODIES; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; WITHANOLIDES;

EID: 84940197335     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13402     Document Type: Article

References (55)

1. Herrmann, H., Bar, H., Kreplak, L., Strelkov, S. V. & Aebi, U. Intermediate flaments: from cell architecture to nanomechanics. Nature reviews. Molecular cell biology 8, 562-573, doi: 10.1038/nrm2197 (2007).
2. Herrmann, H. et al. Structure and assembly properties of the intermediate flament protein vimentin: the role of its head, rod and tail domains. Journal of molecular biology 264, 933-953, doi: 10.1006/jmbi.1996.0688 (1996).
3. Parry, D. A., Strelkov, S. V., Burkhard, P., Aebi, U. & Herrmann, H. Towards a molecular description of intermediate flament structure and assembly. Experimental cell research 313, 2204-2216, doi: 10.1016/j.yexcr.2007.04.009 (2007).
4. Sihag, R. K., Inagaki, M., Yamaguchi, T., Shea, T. B. & Pant, H. C. Role of phosphorylation on the structural dynamics and function of types III and IV intermediate flaments. Experimental cell research 313, 2098-2109, doi: 10.1016/j.yexcr.2007.04.010 (2007).
5. Vuoriluoto, K. et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30, 1436-1448, doi: 10.1038/onc.2010.509 (2011).
6. Ivaska, J., Pallari, H. M., Nevo, J. & Eriksson, J. E. Novel functions of vimentin in cell adhesion, migration, and signaling. Experimental cell research 313, 2050-2062, doi: 10.1016/j.yexcr.2007.03.040 (2007).
7. Perlson, E. et al. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. Journal of molecular biology 364, 938-944, doi: 10.1016/j.jmb.2006.09.056 (2006).
8. Zhu, Q. S. et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30, 457-470, doi: 10.1038/onc.2010.421 (2011).
9. Havel, L. S., Kline, E. R., Salgueiro, A. M. & Marcus, A. I. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene, doi: 10.1038/onc.2014.123 (2014).
10. Byun, Y. et al. Caspase cleavage of vimentin disrupts intermediate flaments and promotes apoptosis. Cell death and diferentiation 8, 443-450, doi: 10.1038/sj.cdd.4400840 (2001).
11. Burikhanov, R. et al. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nature chemical biology 10, 924-926, doi: 10.1038/nchembio.1631 (2014).
12. Pan, Y. et al. Enoxaparin Sensitizes Human Non-Small-Cell Lung Carcinomas to Geftinib by Inhibiting DOCK1 Expression, Vimentin Phosphorylation, and Akt Activation. Molecular pharmacology 87, 378-390, doi: 10.1124/mol.114.094425 (2015).
13. Richardson, F. et al. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second-or third-line therapy. Anticancer research 32, 537-552 (2012).
14. Tiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature reviews. Molecular cell biology 7, 131-142, doi: 10.1038/nrm1835 (2006).
15. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nature reviews. Molecular cell biology 15, 178-196, doi: 10.1038/nrm3758 (2014).
16. Otsuki, S. et al. Vimentin expression is associated with decreased survival in gastric cancer. Oncology reports 25, 1235-1242, doi: 10.3892/or.2011.1185 (2011).
17. Yamashita, N. et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. Journal of cancer research and clinical oncology 139, 739-746, doi: 10.1007/s00432-013-1376-6 (2013).
18. Dauphin, M. et al. Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung cancer 81, 117-122, doi: 10.1016/j.lungcan.2013.03.011 (2013).
19. Satelli, A. & Li, S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and molecular life sciences: CMLS 68, 3033-3046, doi: 10.1007/s00018-011-0735-1 (2011).
20. Bargagna-Mohan, P. et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate flament protein vimentin. Chemistry & biology 14, 623-634, doi: 10.1016/j.chembiol.2007.04.010 (2007).
21. Wu, K. J. et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta pharmacologica Sinica 30, 1162-1168, doi: 10.1038/aps.2009.94 (2009).
22. Dong, T. T. et al. Salinomycin selectively targets 'CD133+ ' cell subpopulations and decreases malignant traits in colorectal cancer lines. Annals of surgical oncology 18, 1797-1804, doi: 10.1245/s10434-011-1561-2 (2011).
23. Ho, C. L., Martys, J. L., Mikhailov, A., Gundersen, G. G. & Liem, R. K. Novel features of intermediate flament dynamics revealed by green fuorescent protein chimeras. Journal of cell science 111 (Pt 13), 1767-1778 (1998).
24. Chang, L. et al. The dynamic properties of intermediate flaments during organelle transport. Journal of cell science 122, 2914-2923, doi: 10.1242/jcs.046789 (2009).
25. Kajita, M. et al. Filamin acts as a key regulator in epithelial defence against transformed cells. Nature communications 5, 4428, doi: 10.1038/ncomms5428 (2014).
26. Mendez, M. G., Kojima, S. & Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB journal: ofcial publication of the Federation of American Societies for Experimental Biology 24, 1838-1851, doi: 10.1096/f.09-151639 (2010).
27. Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446-448, doi: 10.1038/363446a0 (1993).
28. Burgess, A., Lorca, T. & Castro, A. Quantitative live imaging of endogenous DNA replication in mammalian cells. PloS one 7, e45726, doi: 10.1371/journal.pone.0045726 (2012).
29. Rothbauer, U. et al. Targeting and tracing antigens in live cells with fuorescent nanobodies. Nature methods 3, 887-889, doi: 10.1038/nmeth953 (2006).
30. Helma, J. et al. Direct and dynamic detection of HIV-1 in living cells. PloS one 7, e50026, doi: 10.1371/journal.pone.0050026 (2012).
31. Li, T. et al. Cell-penetrating anti-GFAP VHH and corresponding fuorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifcally recognize astrocytes: application to brain imaging. FASEB journal: ofcial publication of the Federation of American Societies for Experimental Biology 26, 3969-3979, doi: 10.1096/f.11-201384 (2012).
32. Van Audenhove, I. et al. Mapping cytoskeletal protein function in cells by means of nanobodies. Cytoskeleton 70, 604-622, doi: 10.1002/cm.21122 (2013).
33. Rocchetti, A., Hawes, C. & Kriechbaumer, V. Fluorescent labelling of the actin cytoskeleton in plants using a cameloid antibody. Plant methods 10, 12, doi: 10.1186/1746-4811-10-12 (2014).
34. Traenkle, B. et al. Monitoring interactions and dynamics of endogenous beta-catenin with intracellular nanobodies in living cells. Molecular & cellular proteomics: MCP, doi: 10.1074/mcp.M114.044016 (2015).
35. Panza, P., Maier, J., Schmees, C., Rothbauer, U. & Sollner, C. Live imaging of endogenous protein dynamics in zebrafsh using chromobodies. Development 142, 1879-1884, doi: 10.1242/dev.118943 (2015).
36. Nguyen, V. K., Hamers, R., Wyns, L. & Muyldermans, S. Camel heavy-chain antibodies: diverse germline V(H)H and specifc mechanisms enlarge the antigen-binding repertoire. The EMBO journal 19, 921-930, doi: 10.1093/emboj/19.5.921 (2000).
37. Rothbauer, U. et al. A versatile nanotrap for biochemical and functional studies with fuorescent fusion proteins. Molecular & cellular proteomics: MCP 7, 282-289, doi: 10.1074/mcp.M700342-MCP200 (2008).
38. Fridy, P. C. et al. A robust pipeline for rapid production of versatile nanobody repertoires. Nature methods 11, 1253-1260, doi: 10.1038/nmeth.3170 (2014).
39. Chernyatina, A. A., Nicolet, S., Aebi, U., Herrmann, H. & Strelkov, S. V. Atomic structure of the vimentin central alpha-helical domain and its implications for intermediate flament assembly. Proceedings of the National Academy of Sciences of the United States of America 109, 13620-13625, doi: 10.1073/pnas.1206836109 (2012).
40. Helfand, B. T. et al. Vimentin organization modulates the formation of lamellipodia. Molecular biology of the cell 22, 1274-1289, doi: 10.1091/mbc.E10-08-0699 (2011).
41. Kawata, M. et al. TGF-beta-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-infammatory cytokines derived from RAW 264.7 macrophage cells. Journal of biochemistry 151, 205-216, doi: 10.1093/jb/mvr136 (2012).
42. Liu, N. et al. Inhibition of cell migration by ouabain in the A549 human lung cancer cell line. Oncology letters 6, 475-479, doi: 10.3892/ol.2013.1406 (2013).
43. Kim, E. Y. et al. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3beta signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Respiratory research 15, 26, doi: 10.1186/1465-9921-15-26 (2014).
44. Wu, Y., Zhang, X., Salmon, M., Lin, X. & Zehner, Z. E. TGFbeta1 regulation of vimentin gene expression during diferentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochimica et biophysica acta 1773, 427-439, doi: 10.1016/j.bbamcr.2006.11.017 (2007).
45. Tirino, V. et al. TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell death & disease 4, e620, doi: 10.1038/cddis.2013.144 (2013).
46. Shohat, B., Gitter, S., Abraham, A. & Lavie, D. Antitumor activity of withaferin A (NSC-101088). Cancer chemotherapy reports. Part 1 51, 271-276 (1967).
47. Mohan, R. et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7, 115-122, doi: 10.1007/s10456-004-1026-3 (2004).
48. Taiparambil, J. T. et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. International journal of cancer. Journal international du cancer 129, 2744-2755, doi: 10.1002/ijc.25938 (2011).
49. Lee, J., Hahm, E. R., Marcus, A. I. & Singh, S. V. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Molecular carcinogenesis, doi: 10.1002/mc.22110 (2013).
50. De Genst, E. et al. Molecular basis for the preferential clef recognition by dromedary heavy-chain antibodies. Proceedings of the National Academy of Sciences of the United States of America 103, 4586-4591, doi: 10.1073/pnas.0505379103 (2006).
51. Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82, 775-797, doi: 10.1146/annurev-biochem-063011-092449 (2013).
52. Ries, J., Kaplan, C., Platonova, E., Eghlidi, H. & Ewers, H. A simple, versatile method for GFP-based super-resolution microscopy via nanobodies. Nature methods 9, 582-584, doi: 10.1038/nmeth.1991 (2012).
53. Panza, P., Maier, J., Schmees, C., Rothbauer, U. & Söllner, C. Live imaging of endogenous protein dynamics in zebrafsh using chromobodies. Development (2015, accepted).
54. Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nature structural & molecular biology 17, 133-138, doi: 10.1038/nsmb.1727 (2010).
55. Chua, K. N. et al. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PloS one 7, e33183, doi: 10.1371/journal.pone.0033183 (2012).